Everest Group Ltd (EG) Stock News

A securities class action lawsuit has been filed against FuelCell Energy, Inc. (FCEL) for allegedly making false and misleading statements regarding manufacturing capacity, production rates, and profitability. The lawsuit covers purchases between June 24, 2026 and September 1, 2026, with a lead plaintiff deadline of November 10, 2026. Investors who purchased FCEL securities during this period may be eligible for compensation.

A securities class action lawsuit has been filed against XTI Aerospace, Inc. for allegedly making materially false and misleading statements during April 15 - August 17, 2026. The lawsuit claims senior executives engaged in undisclosed activities that affected disclosure controls and prevented timely earnings report filings. Investors who purchased securities during this period may be eligible for compensation. The deadline to serve as lead plaintiff is October 27, 2026.

Rosen Law Firm is soliciting investors who purchased Papa John's International (PZZA) stock between August 7, 2025 and August 5, 2026 to join a securities class action lawsuit. The lawsuit alleges that Papa John's made materially false and misleading statements about its transformation efforts, which were taking longer than expected and failed to prevent market share losses, ultimately requiring a shift toward increased promotional efforts.

Rosen Law Firm is notifying investors about securities class action lawsuits, including one against Hyliion Holdings Corp. for allegedly making false statements about its VFG Holdings partnership and commercial pipeline credibility. The firm is seeking a lead plaintiff by October 27, 2026, and encourages affected investors to join the litigation.

Chaince Securities, LLC has been engaged as the exclusive sales agent for Magic Empire Global Limited's (NASDAQ: MEGL) $100 million at-the-market equity offering program. The offering allows MEGL to sell Class A ordinary shares at prevailing market prices, with proceeds intended for working capital and general corporate purposes. This engagement reflects Chaince's expansion of its equity capital markets platform serving Nasdaq-listed issuers.

Cullinan Therapeutics announced the initiation of a New Drug Application (NDA) submission to the FDA for zipalertinib in combination with platinum-based chemotherapy for treating previously untreated EGFR exon 20 insertion NSCLC. The Phase 3 REZILIENT3 trial met its primary endpoint, demonstrating statistically significant improvement in median progression-free survival. The NDA submission is expected to be completed by year-end 2026 under the FDA's Real-Time Oncology Review program.

Lockheed Martin's Rotary and Mission Systems business received a $94.2 million contract modification from the U.S. Navy to support continued development and integration of the AEGIS Combat System for the Royal Canadian Navy. The work, funded through the Foreign Military Sales program, will be completed by December 2027 and includes system engineering, software development, and integration testing.

The article recommends a GARP (Growth at a Reasonable Price) investment strategy that combines value and growth investing principles. Four stocks are highlighted as meeting screening criteria with low PEG ratios, discounted valuations, and strong growth potential: Marathon Petroleum (53.3% expected growth), PBF Energy (55.2% five-year growth), Ultrapar Participações (21.4% growth), and Repsol (21% growth). All four stocks carry Zacks Rank #1 or #2 ratings with Value and Growth scores of A or B.

HUTCHMED announced that AstraZeneca has submitted a New Drug Application (NDA) to the FDA for ORPATHYS® (savolitinib) combined with TAGRISSO® (osimertinib) to treat patients with MET-driven EGFR-mutated non-small cell lung cancer who progressed on EGFR-TKI therapy. The submission is supported by the SAFFRON Phase III trial, which demonstrated statistically significant improvements in progression-free survival and overall survival compared to platinum-based chemotherapy.

Palisade Bio announced that its lead program PALI-2108, an oral PDE4 inhibitor prodrug, will be featured in four presentations at UEG Week 2026 in Barcelona. The presentations will showcase Phase 1b findings in fibrostenotic Crohn's disease, early clinical activity in ulcerative colitis, favorable safety and tolerability, gut-targeted exposure, and a biomarker to predict treatment response. PALI-2108 is advancing into Phase 2 clinical development for both ulcerative colitis and Crohn's disease.

HUTCHMED has initiated a Phase Ia global clinical trial of HMPL-A830, a first-in-class antibody-targeted therapy conjugate combining a KRAS inhibitor with an anti-EGFR antibody for treating solid tumors. The first patient was dosed on September 24, 2026. HUTCHMED entered an exclusive development and licensing agreement with GSK on September 3, 2026, granting GSK worldwide rights (excluding Greater China) for development and commercialization.

Ormat Technologies has been selected by the U.S. Department of Energy for up to $35 million in funding to advance Enhanced Geothermal Systems (EGS) at its Dixie Valley, Nevada project ($25 million) and hydrothermal development at its Cove Fort, Utah project ($9.7 million). The projects will involve partnerships with SLB and the University of Utah to demonstrate engineered reservoirs and enhance understanding of geothermal resources.

Constellation Energy Corporation (CEG) outperformed the broader market on September 21, 2026, gaining 2.91% compared to the S&P 500's 1.49% gain. The company is expected to report strong earnings growth of 30.26% YoY with revenue growth of 31.65% YoY. However, the stock trades at a premium valuation (Forward P/E of 20.9 vs. industry average of 17.31) and carries a Zacks Rank #3 (Hold) rating.

A securities class action lawsuit has been filed against Beta Bionics, Inc. (NASDAQ: BBNX) alleging that the company made materially false and misleading statements about its iLet Bionic Pancreas insulin pump. The FDA reportedly raised serious safety concerns, including device malfunctions causing dangerously high insulin dosing and hypoglycemic events, with thousands of complaints filed. The company allegedly failed to implement meaningful corrective actions. Investors who purchased BBNX stock between July 30, 2025 and February 24, 2026 may be eligible for compensation, with a November 3, 2026 deadline to serve as lead plaintiff.

Rosen Law Firm announces a September 22, 2026 deadline for investors to join a securities class action against PROCEPT BioRobotics Corporation. The lawsuit alleges the company made materially false statements regarding its handpiece unit sales and revenues, claiming an undisclosed discount program artificially inflated sales figures, created excess inventory of over 10,000 units, and that the company could not achieve its 2025 guidance.

A securities class action lawsuit has been filed against Rackspace Technology, Inc. for allegedly making false and misleading statements regarding its business operations. The lawsuit claims defendants failed to disclose that enterprise AI efforts would require significant reallocation of resources from the profitable Private Cloud segment, that Public Cloud revenue was declining, and that fiscal year 2026 revenue would be significantly impacted. Investors who purchased securities between May 7, 2026 and July 8, 2026 may be eligible for compensation. The lead plaintiff deadline is September 28, 2026.

In a comparison of two Internet-Software sector stocks, 8x8 (EGHT) emerges as the superior value option compared to Autodesk (ADSK). EGHT has a stronger Zacks Rank (#2 Buy vs #3 Hold), better valuation metrics including a forward P/E of 5.18 versus 16.81, and a Value grade of A compared to ADSK's C grade.

Rosen Law Firm has filed securities class action lawsuits against Blaize Holdings, Hyliion Holdings, and Primoris Services Corporation, alleging false statements and improper revenue recognition. Investors who purchased securities during specified class periods are encouraged to join the litigation before upcoming deadlines, with the lead plaintiff deadline for Blaize set for October 5, 2026.

Rosen Law Firm reminds investors in Cogent Communications Holdings, Inc. (NASDAQ: CCOI) who purchased stock between February 29, 2024 and May 1, 2026 of the September 21, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that defendants made materially false statements regarding optical wavelength backlog, customer demand, revenue targets, dividend sustainability, and undisclosed risks related to insider stock pledging activities.

A securities class action lawsuit has been filed against Regeneron Pharmaceuticals over allegations that the company made false and misleading statements regarding a Phase 3 clinical trial of Fianlimab for melanoma treatment. The trial failed to reach statistical significance on its primary endpoint, causing an $11 billion market cap loss. Investors claim Regeneron concealed flawed statistical assumptions and slow event rates while expressing confidence in the trial's success. The lead plaintiff deadline is September 14, 2026.

Rosen Law Firm is notifying investors in PROCEPT BioRobotics Corporation (NASDAQ: PRCT) of a securities class action lawsuit with a September 22, 2026 lead plaintiff deadline. The lawsuit alleges that PROCEPT made materially false statements regarding its sales practices, including use of undisclosed discount programs that artificially inflated handpiece unit sales and revenues, created excess inventory of over 10,000 units, and made unachievable 2025 guidance. Investors with losses exceeding $100,000 are encouraged to seek counsel.

Pomerantz Law Firm has filed class action lawsuits against Regeneron Pharmaceuticals, Capricor Therapeutics, and GPGI, Inc. for alleged securities fraud. The primary focus is on Regeneron, where a Phase III clinical trial for Fianlimab-Libtayo failed to meet its primary endpoint, causing the stock to decline significantly on two separate occasions in April and May 2026. Investors with losses are urged to contact the firm by September 14, 2026, to potentially become lead plaintiffs.

Sky Blue Cinematix has been appointed as the exclusive worldwide brand-integration partner for two upcoming feature films from Tested Films: the action thriller 'Habeas Corpus' and the neo-noir romantic mystery 'Blurred', both directed by Ben Cookson. The partnership will connect international brands with these theatrical productions through in-film integration across all territories.

Phillips Edison & Company (PECO) presents a better value opportunity than Regency Centers (REG) based on Zacks Rank and Style Scores analysis. PECO holds a #2 Buy rating with a Value grade of B, while REG has a #3 Hold rating with a Value grade of D. PECO's forward P/E of 14.07 and PEG ratio of 2.02 are more favorable than REG's forward P/E of 15.49 and PEG ratio of 4.47.

Rogers and OEG Sports & Entertainment announced a 10-year extension of their strategic partnership, securing Rogers Place as the home of the Edmonton Oilers through 2036. To celebrate the arena's 10-year anniversary, Rogers is giving away over 1,500 tickets to customers throughout the season, including 300 for the Home Opener on September 29. The extension builds on an unprecedented sponsorship deal signed in 2013 and includes extensive brand placements and advertising across the arena.

Rogers and OEG Sports & Entertainment announced a 10-year partnership extension through 2036, making Rogers Place the home of the Edmonton Oilers. As part of the celebration of Rogers Place's 10th anniversary, Rogers will distribute over 1,500 tickets to customers during the season, including 300 for the home opener on September 29 against Vancouver Canucks. The partnership includes media rights through Sportsnet and various fan engagement initiatives.

Rosen Law Firm has filed a class action lawsuit against Innventure, Inc. (NASDAQ: INV) on behalf of investors who purchased securities between November 17, 2025 and August 13, 2026. The lawsuit alleges that defendants made materially false and misleading statements regarding Accelsius Holdings LLC's transformative deal with DarkNX, which allegedly was unlikely to materialize, and that revenue and cash flow targets for 2026 were overstated. Investors must move the court by October 27, 2026 to serve as lead plaintiff.

Rosen Law Firm is seeking lead plaintiffs for a securities class action lawsuit against Alibaba Group Holding Limited. The lawsuit alleges that Alibaba made false and misleading statements regarding its control by the Chinese Ministry of Industry and Information Technology (MIIT), which would classify it as a Chinese military company under the National Defense Authorization Act, and failed to disclose ongoing distillation attacks against third-party AI models. The lead plaintiff deadline is October 5, 2026.

Rosen Law Firm is notifying investors of securities class action lawsuits against Blaize Holdings, GoDaddy Inc., and Rackspace Technology. The lawsuits allege false statements, improper revenue recognition, and misleading disclosures. Investors have until specified deadlines to join as lead plaintiffs or class members.

eGain reported Q2 2026 earnings of $0.08 per share, beating consensus estimates by 167% and surpassing revenue expectations. However, the stock has declined 29.7% year-to-date versus the S&P 500's 12% gain. The company received a Zacks Rank #3 (Hold) rating with mixed estimate revisions. Meanwhile, Micron is expected to report quarterly earnings of $31.39 per share with revenues of $50.76 billion, representing significant year-over-year growth.